Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAGANINI Phase 2b dose-finding study of eliapixant (BAY 1817080) in refractory and/or unexplained chronic cough
jRCT2031200185Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of eliapixant in refractory chronic cough (RCC) and chronic idiopathic cough (CIC) (4 arms), sponsored by Bayer. Primary endpoint: Change from baseline in 24-hour cough count at Week 12. Started Oct 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on jRCT2031200185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200185.